title: Evoked Potentials and Memory/Cognition Tests Validate Brain Atrophy as Measured by 3T MRI (NeuroQuant) in Cognitively Impaired Patients.
abstract: To our knowledge, this is the largest study evaluating relationships between 3T Magnetic Resonance Imaging (MRI) and P300 and memory/cognitive tests in the literature. The 3T MRI using NeuroQuant has an increased resolution 15 times that of 1.5T MRI. Utilizing NeuroQuant 3T MRI as a diagnostic tool in primary care, subjects (N=169; 19-90 years) displayed increased areas of anatomical atrophy: 34.62% hippocampal atrophy (N=54), 57.14% central atrophy (N=88), and 44.52% temporal atrophy (N=69). A majority of these patients exhibited overlap in measured areas of atrophy and were cognitively impaired. These results positively correlated with decreased P300 values and WMS-III (WMS-III) scores differentially across various brain loci. Delayed latency (p=0.0740) was marginally associated with temporal atrophy; reduced fractional anisotropy (FA) in frontal lobes correlated with aging, delayed P300 latency, and decreased visual and working memory (p=0.0115). Aging and delayed P300 latency correlated with lower FA. The correlation between working memory and reduced FA in frontal lobes is marginally significant (p=0.0787). In the centrum semiovale (CS), reduced FA correlated with visual memory (p=0.0622). Lower demyelination correlated with higher P300 amplitude (p=0.0002). Compared to males, females have higher demyelination (p=0.0064). Along these lines, the higher the P300 amplitude, the lower the bilateral atrophy (p=0.0165). Hippocampal atrophy correlated with increased auditory memory and gender, especially in males (p=0.0087). In considering temporal lobe atrophy correlations: delayed P300 latency and high temporal atrophy (p=0.0740); high auditory memory and low temporal atrophy (p=0.0417); and high working memory and low temporal atrophy (p=0.0166). Central atrophy correlated with aging and immediate memory (p=0.0294): the higher the immediate memory, the lower the central atrophy. Generally, the validation of brain atrophy by P300 and WMS-III could lead to cost-effective methods utilizable in primary care medicine following further confirmation.
authors.affiliation: Department of Psychiatry, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, Florida, United States of America; Department of Clinical Neurology, PATH Foundation NY, New York, New York, United States of America.
authors.forename: Eric R
authors.initials: ER
authors.lastname: Braverman
authors.affiliation: Department of Psychiatry, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, Florida, United States of America; Department of Clinical Neurology, PATH Foundation NY, New York, New York, United States of America; Human Integrated Services, University of Vermont, Center for Clinical and Translational Science, College of Medicine, Burlington, Vermont, United States of America; Department of Addiction Services, Dominion Diagnostics, LLC., North Kingstown, Rhode Island, United States of America.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Blum
authors.affiliation: Alpha 3T MRI & Diagnostic Imaging, New York, New York, United States of America.
authors.forename: Karl L
authors.initials: KL
authors.lastname: Hussman
authors.affiliation: Department of Management Science and Statistics, University of Texas at San Antonio, San Antonio, Texas, United States of America.
authors.forename: David
authors.initials: D
authors.lastname: Han
authors.affiliation: Department of Clinical Neurology, PATH Foundation NY, New York, New York, United States of America.
authors.forename: Kristina
authors.initials: K
authors.lastname: Dushaj
authors.affiliation: Department of Clinical Neurology, PATH Foundation NY, New York, New York, United States of America.
authors.forename: Mona
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Clinical Neurology, PATH Foundation NY, New York, New York, United States of America.
authors.forename: Gabriela
authors.initials: G
authors.lastname: Marin
authors.affiliation: Department of Psychiatry, Neuroimaging Center, University Of Minnesota School of Medicine, Minneapolis, Minnesota, United States of America.
authors.forename: Rajendra D
authors.initials: RD
authors.lastname: Badgaiyan
authors.affiliation: Department of Clinical Neurology, PATH Foundation NY, New York, New York, United States of America.
authors.forename: Richard
authors.initials: R
authors.lastname: Smayda
authors.affiliation: Department of Psychiatry, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, Florida, United States of America.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Gold
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D001284:Atrophy / Q000473:pathology / Q000503:physiopathology; D001921:Brain / Q000473:pathology* / Q000503:physiopathology; D003071:Cognition; D003072:Cognition Disorders / Q000473:pathology* / Q000503:physiopathology; D018913:Event-Related Potentials, P300; D005071:Evoked Potentials; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008568:Memory; D008875:Middle Aged; D009483:Neuropsychological Tests; D055815:Young Adult